LINC 2025 - 10-year outcomes of covered endovascular reconstruction of the aortic bifurcation (CERAB) suggests the technique is an encouraging treatment option for extensive aortoiliac occlusive disease (AIOD) when compared to open surgery.
Dr Peter Goverde (Vascular Clinic ZAS Cadix Hospital, Antwerp, BE) joins us to discuss the prospective data collection and long-term retrospective analysis investigating the CERAB technique in patients with extensive AIOD and TASC C and D lesions. A high population of patients also had diabetes, CV comorbidities, and received previous peripheral and cardiac interventions. The primary outcome measures were the patency rates.
Findings showed CERAB resulted in better outcomes when treating AIOD patients who had no previous interventions or stent placements. CERAB also resulted in encouraging 10-year patency rates and a high rate of freedom from clinically driven target lesion revascularisation.
Interview Questions:
- What is the current research landscape for CERAB treatment for AIOD?
- What is the importance behind the trial?
- Could you further explain the study design and patient population?
- What are your key findings, and did any complications occur during long-term follow up?
- Has your patient selection or technique evolved based on these outcomes?
Recorded remotely from Antwerp, 2025
Editors: Yazmin Sadik, Jordan Rance
Videographers: David Ben-Harosh, Dan Brent
Support: This is an independent interview produced by Radcliffe Vascular.
Comments